NCT01398748View on ClinicalTrials.gov

Intranasal Glutathione in Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Parkinson's Disease (PD)
Interventions
DRUG

Intranasal glutathione - (in)GSH

Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants

DRUG

Intranasal glutathione - (in)GSH

Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants

DRUG

Saline Intranasal Delivery

Saline administration 1ml 3x/day 12 weeks in 15 participants

Trial Locations (1)

98023

Bastyr Clinical Research Center, Kenmore

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Bastyr University

OTHER

NCT01398748 - Intranasal Glutathione in Parkinson's Disease | Biotech Hunter | Biotech Hunter